NCT04192292View on ClinicalTrials.gov

Study of Sulphonylurea Synergy With DPP4 Inhibitors

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

December 2, 2020

Study Completion Date

December 2, 2020

Conditions
Type 2 Diabetes
Interventions
DRUG

Sulfonylurea

Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.

DRUG

DPP4 Inhibitor

Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.

Trial Locations (1)

DD1 9SY

Ninewells Hospital and Medical School, Dundee

All Listed Sponsors
lead

University of Dundee

OTHER

NCT04192292 - Study of Sulphonylurea Synergy With DPP4 Inhibitors | Biotech Hunter | Biotech Hunter